New InhA Inhibitors Based on Expanded Triclosan and <i>Di</i>-Triclosan Analogues to Develop a New Treatment for Tuberculosis

• Main Authors: Sarentha Chetty (Author), Tom Armstrong (Author), Shalu Sharma Kharkwal (Author), William C. Drewe (Author), Cristina I. De Matteis (Author), Dimitrios Evangelopoulos (Author), Sanjib Bhakta (Author), Neil R. Thomas (Author)
• Format: Book
• Published: MDPI AG, 2021-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely c...